PURPOSE: Sulfur mustard (SM) induces acute ocular lesions, including erosions and inflammation that may be followed by delayed injuries expressed by epithelial defects and neovascularization (NV). Based on the matrix metalloproteinases (MMPs) activity, we evaluated the clinical and biochemical effects of topical treatment with doxycycline, an MMP inhibitor, targeted to the various injury stages. METHODS: Rabbit eyes were exposed to SM vapor. A clinical follow-up was carried out up to 2 months. Tear fluid and cornea samples were collected at different time points for measurements of MMPs activity by zymography. Efficacy of a post-exposure topical doxycycline (2 mg/ml in phosphate buffer saline, ×4/d), targeted to the different phases of the clinical injury, was evaluated. RESULTS: Elevated MMP-9 and MMP-2 activities were found in all corneas during the acute injury and in vascularized corneas during the delayed pathology. In the tear fluid, high MMP-9 activity and negligible MMP-2 activity were found in all the exposed eyes until after the appearance of the delayed pathology symptoms. Prolonged doxycycline treatment reduced MMP-9 activity in the tear fluid. During the acute phase, doxycycline treatment reduced corneal MMP-9 activity and the severity of the injury. Targeting the delayed pathology, doxycycline was clinically efficient only when treatment began before NV appearance. CONCLUSIONS: This in vivo study showed the involvement of MMP-9 and MMP-2 during different phases of the SM-induced ocular injury, and the potential of doxycycline treatment as a post exposure measure for reducing the acute injury and as a preventive therapy for ameliorating the delayed pathology. The tear fluid provided a non-invasive method for continuous follow-up of MMPs activity and revealed additional beneficial aspects of injury and the treatment.
PURPOSE:Sulfur mustard (SM) induces acute ocular lesions, including erosions and inflammation that may be followed by delayed injuries expressed by epithelial defects and neovascularization (NV). Based on the matrix metalloproteinases (MMPs) activity, we evaluated the clinical and biochemical effects of topical treatment with doxycycline, an MMP inhibitor, targeted to the various injury stages. METHODS:Rabbit eyes were exposed to SM vapor. A clinical follow-up was carried out up to 2 months. Tear fluid and cornea samples were collected at different time points for measurements of MMPs activity by zymography. Efficacy of a post-exposure topical doxycycline (2 mg/ml in phosphate buffer saline, ×4/d), targeted to the different phases of the clinical injury, was evaluated. RESULTS: Elevated MMP-9 and MMP-2 activities were found in all corneas during the acute injury and in vascularized corneas during the delayed pathology. In the tear fluid, high MMP-9 activity and negligible MMP-2 activity were found in all the exposed eyes until after the appearance of the delayed pathology symptoms. Prolonged doxycycline treatment reduced MMP-9 activity in the tear fluid. During the acute phase, doxycycline treatment reduced cornealMMP-9 activity and the severity of the injury. Targeting the delayed pathology, doxycycline was clinically efficient only when treatment began before NV appearance. CONCLUSIONS: This in vivo study showed the involvement of MMP-9 and MMP-2 during different phases of the SM-induced ocular injury, and the potential of doxycycline treatment as a post exposure measure for reducing the acute injury and as a preventive therapy for ameliorating the delayed pathology. The tear fluid provided a non-invasive method for continuous follow-up of MMPs activity and revealed additional beneficial aspects of injury and the treatment.
Authors: Dinesh G Goswami; Rama Kant; David A Ammar; Dileep Kumar; Robert W Enzenauer; J Mark Petrash; Neera Tewari-Singh; Rajesh Agarwal Journal: Exp Mol Pathol Date: 2019-06-21 Impact factor: 3.362
Authors: Marion K Gordon; Andrea DeSantis-Rodrigues; Rita Hahn; Peihong Zhou; Yokechen Chang; Kathy K H Svoboda; Donald R Gerecke Journal: Ann N Y Acad Sci Date: 2016-08 Impact factor: 5.691
Authors: Neera Tewari-Singh; Dinesh G Goswami; Rama Kant; David A Ammar; Dileep Kumar; Robert W Enzenauer; Robert P Casillas; Claire R Croutch; J Mark Petrash; Rajesh Agarwal Journal: Toxicol Sci Date: 2017-12-01 Impact factor: 4.849
Authors: Andrea DeSantis-Rodrigues; Yoke-Chen Chang; Rita A Hahn; Iris P Po; Peihong Zhou; C Jeffrey Lacey; Abhilash Pillai; Sherri C Young; Robert A Flowers; Michael A Gallo; Jeffrey D Laskin; Donald R Gerecke; Kathy K H Svoboda; Ned D Heindel; Marion K Gordon Journal: Invest Ophthalmol Vis Sci Date: 2016-04 Impact factor: 4.799